Chromadex Corp (CDXC)

$1.52

Market is closed - opens 8 PM, 26 Feb 2024

Insights on Chromadex Corp

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 22.55M → 19.49M (in $), with an average decrease of 7.0% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -2.19M → -959.0K (in $), with an average increase of 128.5% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 74.4% return, outperforming this stock by 80.6%

Performance

  • $1.48
    $1.54
    $1.52
    downward going graph

    2.63%

    Downside

    Day's Volatility :3.9%

    Upside

    1.3%

    downward going graph
  • $1.25
    $1.99
    $1.52
    downward going graph

    17.76%

    Downside

    52 Weeks Volatility :37.19%

    Upside

    23.62%

    downward going graph

Returns

PeriodChromadex CorpSector (Health Care)Index (Russel 2000)
3 Months
5.56%
12.8%
0.0%
6 Months
1.33%
10.8%
0.0%
1 Year
-11.11%
15.1%
-6.4%
3 Years
-81.86%
30.2%
-19.6%

Highlights

Market Capitalization
114.2M
Book Value
$0.36
Earnings Per Share (EPS)
-0.09
PEG Ratio
0.0
Wall Street Target Price
4.85
Profit Margin
-7.76%
Operating Margin TTM
-5.88%
Return On Assets TTM
-8.67%
Return On Equity TTM
-26.77%
Revenue TTM
83.4M
Revenue Per Share TTM
1.12
Quarterly Revenue Growth YOY
14.299999999999999%
Gross Profit TTM
42.8M
EBITDA
-5.8M
Diluted Eps TTM
-0.09
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.09
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
-0.03
EPS Estimate Next Quarter
-0.02

Analyst Recommendation

Buy
    80%Buy
    20%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for Chromadex Corp(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
9
9
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 219.08%

Current $1.52
Target $4.85

Company Financials

FY18Y/Y Change
Revenue
31.6M
↑ 48.84%
Net Income
-33.3M
↑ 192.82%
Net Profit Margin
-105.57%
↓ 51.91%
FY19Y/Y Change
Revenue
46.3M
↑ 46.69%
Net Income
-31.5M
↓ 5.54%
Net Profit Margin
-67.99%
↑ 37.58%
FY20Y/Y Change
Revenue
59.3M
↑ 28.01%
Net Income
-18.5M
↓ 41.27%
Net Profit Margin
-31.19%
↑ 36.8%
FY21Y/Y Change
Revenue
67.4M
↑ 13.82%
Net Income
-25.6M
↑ 38.27%
Net Profit Margin
-37.89%
↓ 6.7%
FY22Y/Y Change
Revenue
72.1M
↑ 6.82%
Net Income
-14.4M
↓ 43.46%
Net Profit Margin
-20.05%
↑ 17.84%
FY23Y/Y Change
Revenue
83.4M
↑ 15.71%
Net Income
-6.5M
↓ 55.22%
Net Profit Margin
-7.76%
↑ 12.29%
Q2 FY22Q/Q Change
Revenue
16.7M
↓ 3.05%
Net Income
-6.4M
↓ 17.31%
Net Profit Margin
-38.29%
↑ 6.6%
Q3 FY22Q/Q Change
Revenue
17.1M
↑ 1.98%
Net Income
1.1M
↓ 117.09%
Net Profit Margin
6.42%
↑ 44.71%
Q4 FY22Q/Q Change
Revenue
21.0M
↑ 23.05%
Net Income
673.0K
↓ 38.54%
Net Profit Margin
3.21%
↓ 3.21%
Q1 FY23Q/Q Change
Revenue
22.6M
↑ 7.43%
Net Income
-1.3M
↓ 297.62%
Net Profit Margin
-5.9%
↓ 9.11%
Q2 FY23Q/Q Change
Revenue
20.3M
↓ 9.9%
Net Income
-2.2M
↑ 64.74%
Net Profit Margin
-10.78%
↓ 4.88%
Q3 FY23Q/Q Change
Revenue
19.5M
↓ 4.07%
Net Income
-959.0K
↓ 56.23%
Net Profit Margin
-4.92%
↑ 5.86%
FY17Y/Y Change
Total Assets
62.7M
↑ 217.55%
Total Liabilities
8.9M
↓ 9.08%
FY18Y/Y Change
Total Assets
42.2M
↓ 32.67%
Total Liabilities
15.1M
↑ 69.34%
FY19Y/Y Change
Total Assets
40.2M
↓ 4.7%
Total Liabilities
19.8M
↑ 31.54%
FY20Y/Y Change
Total Assets
38.4M
↓ 4.69%
Total Liabilities
21.9M
↑ 10.77%
FY21Y/Y Change
Total Assets
57.8M
↑ 50.79%
Total Liabilities
26.1M
↑ 19.05%
FY22Y/Y Change
Total Assets
54.1M
↓ 6.54%
Total Liabilities
25.4M
↓ 2.79%
Q2 FY22Q/Q Change
Total Assets
46.6M
↓ 11.93%
Total Liabilities
25.8M
↓ 4.5%
Q3 FY22Q/Q Change
Total Assets
45.7M
↓ 2.03%
Total Liabilities
24.6M
↓ 4.62%
Q4 FY22Q/Q Change
Total Assets
54.1M
↑ 18.38%
Total Liabilities
25.4M
↑ 3.02%
Q1 FY23Q/Q Change
Total Assets
53.8M
↓ 0.53%
Total Liabilities
25.8M
↑ 1.44%
Q2 FY23Q/Q Change
Total Assets
53.2M
↓ 1.11%
Total Liabilities
26.0M
↑ 1.05%
Q3 FY23Q/Q Change
Total Assets
53.5M
↑ 0.59%
Total Liabilities
26.2M
↑ 0.59%
FY18Y/Y Change
Operating Cash Flow
-20.9M
↑ 113.26%
Investing Cash Flow
-1.8M
↓ 138.57%
Financing Cash Flow
-90.0K
↓ 100.18%
FY19Y/Y Change
Operating Cash Flow
-20.4M
↓ 2.24%
Investing Cash Flow
-249.0K
↓ 85.97%
Financing Cash Flow
16.9M
↓ 18860.0%
FY20Y/Y Change
Operating Cash Flow
-10.6M
↓ 48.14%
Investing Cash Flow
-165.0K
↓ 33.73%
Financing Cash Flow
8.7M
↓ 48.77%
FY21Y/Y Change
Operating Cash Flow
-24.2M
↑ 127.95%
Investing Cash Flow
-409.0K
↑ 147.88%
Financing Cash Flow
36.1M
↑ 317.27%
FY22Y/Y Change
Operating Cash Flow
-15.1M
↓ 37.52%
Investing Cash Flow
-334.0K
↓ 18.34%
Financing Cash Flow
7.7M
↓ 78.79%
Q2 FY22Q/Q Change
Operating Cash Flow
-3.8M
↓ 46.76%
Investing Cash Flow
-85.0K
↑ 240.0%
Financing Cash Flow
-4.0K
↑ 33.33%
Q3 FY22Q/Q Change
Operating Cash Flow
-3.7M
↓ 2.4%
Investing Cash Flow
-52.0K
↓ 38.82%
Financing Cash Flow
-18.0K
↑ 350.0%
Q4 FY22Q/Q Change
Operating Cash Flow
-328.0K
↓ 91.23%
Investing Cash Flow
-172.0K
↑ 230.77%
Financing Cash Flow
7.7M
↓ 42761.11%
Q1 FY23Q/Q Change
Operating Cash Flow
2.8M
↓ 951.22%
Investing Cash Flow
-91.0K
↓ 47.09%
Financing Cash Flow
-1000.0
↓ 100.01%
Q2 FY23Q/Q Change
Operating Cash Flow
3.3M
↑ 17.48%
Investing Cash Flow
-5.0K
↓ 94.51%
Financing Cash Flow
-10.0K
↑ 900.0%

Technicals Summary

Sell

Neutral

Buy

Chromadex Corp is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Chromadex Corp
Chromadex Corp
3.4%
1.33%
-11.11%
-81.86%
-81.86%
Moderna, Inc.
Moderna, Inc.
-6.18%
-13.82%
-30.24%
-34.99%
345.54%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
3.41%
18.17%
29.48%
116.51%
133.41%
Novo Nordisk A/s
Novo Nordisk A/s
16.81%
32.44%
72.22%
241.3%
399.49%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
0.03%
22.87%
49.66%
101.95%
130.83%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Chromadex Corp
Chromadex Corp
NA
NA
0.0
-0.09
-0.27
-0.09
NA
0.36
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-12.46
-0.22
-0.07
NA
35.32
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
27.77
27.77
1.97
44.85
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
45.7
45.7
4.49
3.31
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
30.77
30.77
0.58
16.74
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Chromadex Corp
Chromadex Corp
Buy
$114.2M
-81.86%
NA
-7.76%
Moderna, Inc.
Moderna, Inc.
Buy
$37.9B
345.54%
24.73
-38.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$105.9B
133.41%
27.77
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$550.7B
399.49%
45.7
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$110.2B
130.83%
30.77
36.68%

Institutional Holdings

  • Vanguard Group Inc

    4.05%
  • Tieton Capital Management, LLC

    3.26%
  • ICONIQ Capital, LLC

    1.73%
  • BlackRock Inc

    1.21%
  • Geode Capital Management, LLC

    0.67%
  • Renaissance Technologies Corp

    0.59%

Corporate Announcements

  • Chromadex Corp Earnings

    Chromadex Corp’s price-to-earnings ratio stands at None

    Read More

Company Information

chromadex corp. is an integrated, global nutraceutical company devoted to improving the way people age. chromadex scientists partner with leading universities and research institutions worldwide to uncover the full potential of nad and identify and develop novel, science-based ingredients including pteropure® pterostilbene; purenergy®, a caffeine-pteropure® co-crystal; anthorigin™, anthocyanins and niagen® nicotinamide riboside - sold directly to consumers as the supplement, tru niagen®. tru niagen® is helping the world age better®. for more, visit www.chromadex.com like us on facebook here: https://www.facebook.com/chromadex or follow us on twitter @chromadex chromadex® is publicly-traded company (nasdaq:cdxc).

Organization
Chromadex Corp
Employees
113
CEO
Mr. Frank Louis Jaksch Jr.
Industry
Process Industries

FAQs